FindTrial
Sign In

Exploring the Role of Dapagliflozin in Chronic Kidney Disease Progression

Efficacy of dapagliflozin in spectrum of chronic kidney disease - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/081391
Enrollment
112
Registered
2025-02-27
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N18- Chronic kidney disease (CKD)

Interventions

Intervention1: DAPAGLIFLOZIN: eGFR 25ml/min/1.73m2 to be given DAPAGLIFLOZIN Control Intervention1: SERUM CREATININE AND UPCR: BASELINE SERUM CREATININE AND UPCR AND COMPARISON AFTER 6 MONTHS OF START

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with type 1 diabetes mellitus., Patients with polycystic kidney disease., Patient with active urinary tract infection.

Exclusion criteria

Exclusion criteria: Patients with type 1 diabetes mellitus., Patients with polycystic kidney disease, Patient with active urinary tract infection.

Design outcomes

Primary

MeasureTime frame
To assess the trend of eGFR / serum creatinine and proteinuria over a period of six months after starting dapagliflozinTimepoint: All parameters will be assessed at the baseline at the time of enrollment at day 1 and 24 weeks after starting dapagliflozin—

Secondary

MeasureTime frame
To look for incidence of urinary tract infection, limb amputation, hypoglycemia in period of six months after starting medicationTimepoint: All parameters will be assessed at the baseline at the time of enrollment at day 1 & 24 weeks after starting dapagliflozin—

Countries

India

Contacts

Public ContactManish Balwani

Datta Meghe Institute of Higher Education and Research

pawartwinkle@gmail.com7719920761

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026